Others find that combining semaglutide with lifestyle changesstructured exercise, protein intake, strength trainingreignites progress without requiring a higher dose
For instance, in August 2025, Viking Therapeutics, a US-based company specializing in metabolic and endocrine disorder treatments, announced positive top-line results from its Phase 2 VENTURE-Oral Dosing trial of VK2735, an investigational oral dual GLP-1/GIP agonist for obesity
Participants under-consumed servings of fruit, grains, dairy, and vegetables compared to MyPlate recommendations
This comparison helps place Peak Wellness alongside a few common alternatives so the trade-offs are easier to see
J., Schwabe R
Figure 2 Figure 3 Meta-analysis of the outcome Pain relief with GLP-1 agonists versus placebo According to the results, ROSE-010 (100 g) considerably lowers the pain intensity when compared to a placebo